0
Lung Cancer: Lung Cancer I |

A Systematic Review and Meta-analysis of Efficacy About COX-2 Inhibitor Plus Chemotherapy Compared to CT Alone in Previously Untreated Non-small Cell Lung Cancer FREE TO VIEW

Xiaoge Wang
Author and Funding Information

The Fourth Affiliated Hospital of China Medical University, Shenyang, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A291. doi:10.1016/j.chest.2016.02.303
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer I

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: A number of randomized controlled trials have observed an efficacy of chemotherapy (CT) plus COX-2 inhibitor versus CT alone in previously untreated locally non-small cell lung cancer (NSCLC). We carried out a systematic review and meta-analysis (MA) of CT plus COX-2 inhibitor in people and mice.

METHODS: Several databases were searched, including CNKI, MEDLINE, EMBASE and others. The endpoints were the response rate, one year survival and side effects in patients while tumor volume of 28 days and tumor weigh of 24 days in mice. We performed a MA of the published data, using a fixed effects model and an additional random effects model, when applicable. The results of the MA are expressed as odds ratio (OR) value, with their corresponding 95% Confidence intervals (CI95%).

RESULTS: The final analysis included 8 trials, comprising 677 patients and 32 mice. The response rate was higher in patients who received the combination of CT plus COX-2 inhibitor (OR=1.44;CI95%=1.04-1.98; p=0.03) with low heterogeneity (Chi2=1.22, df=3 (P=0.75); I2=0%). The one year survival was higher in patients who received CT plus COX-2 inhibitor (OR=1.62, CI95%=1.02-2.59;p=0.04) with low heterogeneity (Chi2=0.69, df=1 (P=041); I2=0%). There was no relevance between CT plus COX-2 inhibitor and CT alone in haematological and non-haematological side effects. In mice, tumor weigh was smaller who received the COX-2 inhibitor (OR=−1.29;CI95%=−2.08∼−0.51; p=0.001) with low heterogeneity (Chi2=0.13, df=1 (P=0.72); I2=0%) and tumor volume was also smaller who received the combination of CT plus COX-2 inhibitor (OR=−1.71;CI95%=−6.80∼−0.63;p=0.02) with high heterogeneity (Chi2=5.73, df=1 (P=0.02); I2=83%).

CONCLUSIONS: The combination of CT plus COX-2 inhibitor increased the response rate and one-year-survival of patients with no change of side effects in NSCLC.

CLINICAL IMPLICATIONS: The combination of CT plus COX-2 inhibitor increased the response rate and one-year-survival of patients with no change of side effects in NSCLC. COX-2 inhibitor may be widely used in clinical.

DISCLOSURE: The following authors have nothing to disclose: Xiaoge Wang

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543